Retina Practice Valuation & Sale Prices: 2026

This report aggregates data from healthcare M&A transaction databases, independent valuation research firms, and publicly available sector studies to provide retina specialist practice owners with a current, data-supported picture of practice valuations as of 2026. The analysis reflects both platform-level and practice-level transactions, with particular attention to the procedural and structural characteristics that distinguish retina from adjacent ophthalmology subspecialties and drive premium buyer interest.

Key Findings:

• Retina commands the highest multiples in ophthalmology. Valuations range from 6x–8x EBITDA for small single-physician practices up to 23x+ for premium platforms, outpacing general ophthalmology across every size category.
• Anti-VEGF injection volume is the core EBITDA driver. High-volume intravitreal injection practices treating AMD, diabetic macular edema, and retinal vein occlusion generate the recurring, predictable revenue that gives institutional buyers confidence.
• Structure matters as much as financials. MSO infrastructure and clinical research participation can create large valuation differences between practices at the same revenue level.
• Pharma distributors have become the dominant buyers. Cencora and McKesson have deployed over $6.5B into retina since 2024, fundamentally repricing the top of the market and signaling a permanent shift away from traditional PE sponsorship.
• Demand fundamentals are durable. The retinal disorder treatment market is projected to nearly double to $35.4B by 2034, driven by aging demographics.

2026 Retina Practice Valuation Multiples by Practice Profile

The table below reflects EV/EBITDA valuation multiple ranges observed across retina practice transactions in the U.S. market, organized by practice scale and profile. Retina consistently commands a premium over general ophthalmology due to its procedural intensity, anti-VEGF injection revenue, and strategic importance to pharmaceutical distribution networks, a dynamic underscored by the sector’s two largest transactions of 2024 and 2026.¹·²·³

The Retina Practice Valuation Table 2026
Practice Profile	Annual Adjusted EBITDA	EV/EBITDA Range	Defining Characteristics
Single-Physician Retina Practice	$500K–$1.5M	6x–8x	Single-site, medical retina focus, injection-dependent revenue
Multi-Physician, Single-Site or 2–3 Locations	$1.5M–$4M	7x–10x	Mixed surgical and medical retina; early ancillary revenue
Small Regional Group	$3M–$8M	8x–12x	4–10 physicians; possible ASC ownership and large research program
Mid-Size Platform	$5M–$15M	10x–14x	Multi-state; heavy clinical research participation
Premium Scale Platform	$15M+	14x–23x+	MSO structure; drug distribution leverage; national footprint

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Three observations stand out from this data:

1. The retina subspecialty commands the highest physician practice multiples in all of ophthalmology. The 14x–23x+ premium platform range reflects retina’s unique intersection of procedural medicine, pharmaceutical distribution economics, and recurring injection revenue, a combination no other ophthalmic subspecialty replicates at scale.¹·⁴
2. Anti-VEGF injection volume is the primary EBITDA driver at most retina practices. Practices administering high volumes of intravitreal agents for AMD, diabetic macular edema, and retinal vein occlusion generate recurring, predictable revenue streams that underwrite institutional buyer confidence across the multiple range.⁵·⁶
3. MSO structure unlocks the top of the valuation range. The 15x–23x+ multiple achieved by Retina Consultants of America reflects an MSO model with pharmaceutical distribution leverage. Practice-level sellers should understand that platform structure and unique synergies (not EBITDA alone) determines access to this range.¹

Key Valuation Drivers and Their Effect on Multiples

The following table reflects the most consistently cited premium and compression factors across retina practice transactions.

Retina Practice Valuation Driver Table — 2026¹·³·⁴
Valuation Driver	Estimated Multiple Effect	Rationale
MSO / Management Infrastructure	↑	Scale, diversity, and management de-risks opportunity for financial and strategic buyers
ASC Ownership (Vitreoretinal-Capable)	↑	High-margin surgical venue; platform expansion asset
Anti-VEGF Injection Volume (High)	↑	Recurring, predictable revenue; pharmaceutical distribution leverage
Clinical Research Participation	↑	Premium positioning; pipeline exposure
Vitreoretinal Surgical Mix	↑	Complex, non-deferrable cases; higher CPT reimbursement
Multi-Physician, Multi-Site Structure	↑	Reduces key-person risk; demonstrates scalability
Commercial Payer Mix (40%+ commercial)	↑	Offsets Medicare reimbursement pressure
Medicare Concentration (70%+)	↓	Reimbursement sensitivity; exposure to CMS fee schedule changes
Single-Physician Owner Dependency	↓	Post-close patient and referral retention risk
Injection-Only Practice (No Surgical Component)	↓	Lower procedural ceiling; less surgical platform value

Source: works cited combined with guidance from internal bankers, based generally on knowledge and experience. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.

Notable Retina M&A Transactions (2020–2026)

The following table highlights the landmark transactions that have set valuation benchmarks and shaped buyer expectations in the retina M&A market since the formation of the first major PE-backed retina MSO in 2020.

Selected Retina and Eye Care M&A Transactions — 2020–2026²·⁸
Year	Transaction	Deal Value	Estimated  Multiple	Buyer Type
2020	Webster Equity Partners forms RCA	$350M investment	—	Private Equity
2022	RCA peak acquisition year	—	—	PE Platform (10 deals)
2024	Cencora acquires RCA from Webster Equity	$4.6B	15x–23x EBITDA (est. per Scope Research)	Strategic / Pharma Distributor
2025	McKesson acquires 80% of Prism Vision Holdings	$850M	—	Strategic / Pharma Distributor
2026	Cencora (via RCA) acquires EyeSouth’s retina business	$1.1B	—	Strategic / Pharma Distributor

Source: Irving Levin Associates, LevinPro HC Database (March 2026); Scope Research, Healthcare M&A Valuation Database (2024); VMG Health (April 2025); Fierce Healthcare (March 2026). Intended for educational purposes only.

Several structural observations emerge from this transaction sequence:

• Three of the five largest transactions in the retina sector have been completed by pharmaceutical distribution companies, not traditional PE sponsors. Cencora (formerly AmerisourceBergen) and McKesson have collectively deployed more than $6.5B into retina care since 2024 alone, signaling a permanent shift in the strategic buyer landscape.²·⁸
• RCA has been responsible for approximately 50% of all retina M&A deals announced since 2019, with 30 acquisitions since its 2020 formation and a peak of 10 deals in 2022. Since the start of 2025, 10 transactions in the retinal care space have been reported.² ·⁸

Retina Market Size and Demand Fundamentals

Retina practices operate within one of the most durable demand environments in outpatient medicine. The conditions driving patient volume (age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion) are chronic, progressive, and largely non-deferrable, creating the recurring injection and surgical revenue that underpins practice valuations and institutional buyer confidence.⁵·⁶·⁹·¹⁰

U.S. and Global Retina Market Data — 2026
Metric	Data Point
Global Retinal Disorder Treatment Market (2024)	$18.3 billion
Projected Retinal Disorder Treatment Market (2034)	~$35.4 billion (6.7% CAGR)
Ophthalmic Anti-VEGF Therapeutics Market (2024)	$16.9+ billion
Anti-VEGF Market CAGR (2025–2034)	5.2%
Intravitreal Injectable Market (2026)	$19.0 billion
Projected Intravitreal Market (2033)	$25.8 billion (4.5% CAGR)
Annual Anti-VEGF Injections Administered (U.S.)	~11 million
Medicare Anti-VEGF Injections (2014–2023 cumulative)	36.4+ million
AMD Treatment Market (2026)	$17.8 billion
AMD Market CAGR	5.7%
Medicare Advantage Enrollment (Eligible Beneficiaries)	54%

Source: Global Market Insights (2025); Persistence Market Research (2025); Coherent Market Insights (2026); Business Research Insights (2025); ScienceDirect / Medicare Trends Study (2026); HealthFMV (2025). Intended for educational purposes only.

Structural demand factors are actively reinforcing the retina M&A outlook through at least 2030.The 65+ population, which carries the highest prevalence of AMD, diabetic retinopathy, and retinal vein occlusion, is the fastest-growing age cohort in the United States. This demographic tailwind is insulated from economic cycles and represents a decade-plus runway of compounding procedure volume for established retina practices.⁴

Connect with the FOCUS Healthcare Team

FOCUS Investment Banking specializes in maximizing transaction value for medical practice owners through our proven quarterback approach to M&A advisory. If you would like to learn more about our healthcare investment banking services or discuss how current market conditions affect the value of your practice, you can reach out to Eric Yetter or Andy Snyder.

Sources

1. Scope Research. Healthcare M&A Valuation Database: Ophthalmology EBITDA Multiples. 2024. scoperesearch.co.
2. Irving Levin Associates. Retina Consultants of America Announces $1.1 Billion Acquisition. March 2026. levinassociates.com.
3. VMG Health. A New Buyer in Physician Practice M&A Emerges. April 2025. vmghealth.com.
4. HealthFMV. Ophthalmology Valuation and M&A Trends. 2025. healthfmv.com.
5. Global Market Insights. Ophthalmic Anti-VEGF Therapeutics Market. 2025. gminsights.com.
6. Persistence Market Research. Intravitreal (IVT) Injectable Market Size and Forecast, 2033. 2025. persistencemarketresearch.com.
7. Stout. Eyes on Ophthalmology for M&A Opportunities. stout.com.
8. Fierce Healthcare. Cencora Acquiring EyeSouth Partners’ Retina Business for $1.1B. March 2026. fiercehealthcare.com.
9. Business Research Insights. Intravitreal Injectable Market Size and Trends Analysis, 2035. 2025. businessresearchinsights.com.
10. Coherent Market Insights. Macular Degeneration Treatment Market Size and Forecast: 2026–2033. 2026. coherentmarketinsights.com.
11. Thompson JT. Private Equity Purchases of Retina Practices. Journal of Vitreoretinal Diseases. July 2023. pmc.ncbi.nlm.nih.gov.